ClinicalTrials.gg
RecruitingNCT06832163Updated May 13, 2026

Close Loop Smart Weaning for INO With PPHN

An interventional study of Nitric Oxide Generation and Delivery System in Persistent Pulmonary Hypertension of the Newborn and Inhaled Nitric Oxide, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Children's Hospital of Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Sex
All
01

Study summary

In contemporary clinical practice concerning the administration of inhaled nitric oxide (iNO) within neonatal intensive care units (NICUs), a stepwise reduction approach is frequently employed in accordance with established neonatal guidelines. Nonetheless, the comparative advantages of a linear reduction strategy-characterized by a gradual decrease in inhalation concentration-over the traditional stepwise method in terms of efficacy and safety have yet to be conclusively established. Furthermore, existing iNO delivery devices necessitate that healthcare professionals manually adjust parameters at intervals dictated by the patient's condition. This reliance on subjective clinical judgment often results in variability and a lack of standardization in the duration of the weaning process. Additionally, the protracted and intricate nature of the weaning procedure considerably heightens the workload for healthcare staff. Importantly, the development of a scientifically grounded, standardized, and real-time feedback mechanism for weaning may enhance clinical outcomes for patients and mitigate the risks associated with inappropriate weaning practices or inconsistent manual interventions. Consequently, this study seeks to leverage the newly introduced "intelligent closed-loop weaning" feature of the latest generation of iNO devices to facilitate automated linear concentration reduction during the weaning process. This innovation aims to alleviate the burden on healthcare personnel while establishing a more standardized and scientifically robust weaning protocol. However, it is noteworthy that there is currently a lack of clinical evidence, both domestically and internationally, regarding the safety and efficacy of this device's weaning protocol, underscoring the urgent need to validate its safety and effectiveness in real-world clinical settings.

02

Conditions studied

  • Persistent Pulmonary Hypertension of the Newborn
  • Inhaled Nitric Oxide

Keywords

  • Inhaled Nitric Oxide
  • Persistent Pulmonary Hypertension of the Newborn
03

In context

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

This study's planned enrollment of 30 is below the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.

Browse Persistent Fetal Circulation Syndrome studies →

Lead sponsor

Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The administration of inhaled nitric oxide (iNO) has commenced or is anticipated to commence for a duration of 24 hours or more, based on a clinical diagnosis of persistent pulmonary hypertension of the newborn (PPHN);
  2. There is a demonstrable positive response to iNO treatment;
  3. The iNO delivery system employed is appropriate and meets the conditional requirements, featuring an intelligent closed-loop offline functionality;
  4. The guardian or legal representative possesses a comprehensive understanding of the potential benefits and risks associated with participation in this study and has expressed a willingness to consent by signing the document.

Exclusion criteria

Exclusion Criteria:

  1. There are established associated with the use of nitric oxide, which include the following conditions:

    1. Severe hypoplasia of the left heart or duct-dependent congenital heart disease;
    2. Life-threatening congenital anomalies and congestive heart failure;
    3. Congenital methemoglobinemia;
    4. Significant hemorrhagic events, such as intracranial hemorrhage, intraventricular hemorrhage, and pulmonary hemorrhage.
  2. Patients with chronic pulmonary conditions and other diseases are not permitted to initiate withdrawal from the inhaled nitric oxide (iNO) treatment within a seven-day period following its administration.
  3. In cases where there is no observable response to iNO or if the duration of use is less than 30 minutes, a strict tapering protocol for withdrawal is not required.
  4. If the concentration of iNO treatment exceeds 20 parts per million (ppm) during the initiation phase or if the starting concentration for withdrawal is below 20 ppm, specific considerations must be taken into account.
  5. Participation in concurrent clinical trials involving other pharmacological agents or medical devices is prohibited.
  6. The investigator may determine that participation in this study is not appropriate for certain individuals.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Inhaled Nitric Oxide (iNO), the initial concentration of NO withdrawal is 20ppm.

    In the initial phase of the study, a total of 10 participants are enrolled in a non-controlled single-group pre-trial. The subsequent phase is organized into two distinct groups, each comprising 10 participants, resulting in a total of 20 subjects. The groups are categorized as follows: ① The experimental group, which utilizes an intelligent closed-loop offline system operating in a linear decline mode; ② The control group, which employs an intelligent closed-loop offline system functioning in a step decline mode.

    Device: Nitric Oxide Generation and Delivery System

Interventions

  • DeviceNitric Oxide Generation and Delivery System

    The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. iNO devices with intelligent closed-loop offline function are required to meet the import and discharge standards. The initial concentration of NO withdrawal is 20ppm. In accordance with the withdrawal criteria outlined in the Chinese Guidelines, it is essential to conduct a comprehensive efficacy evaluation prior to initiating withdrawal. Furthermore, the process of inhaled nitric oxide (iNO) evacuation should commence only if specific conditions are satisfied.

06

What researchers measure

Primary outcomes

  1. The occurrence of nitric oxide (NO) rebound hypoxia during the evacuation process

    The occurrence of nitric oxide (NO) rebound hypoxia during the evacuation process, operationally defined as the frequency of instances in which peripheral capillary oxygen saturation (SpO2) decreased by more than 5% and the fraction of inspired oxygen (FiO2) increased by 15% in order to maintain partial pressure of arterial oxygen (PaO2) above 60 mmHg (with SpO2 ≥ 90%) during the evacuation of NO

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  2. The total duration of inhaled nitric oxide (iNO) evacuation

    The entire length of time required to remove or discontinue the use of iNO.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

Secondary outcomes

  1. Device Alarm Frequency

    The frequency of device alarms recorded during the evacuation process.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  2. NO Concentration Adjustments

    The total number of adjustments made to knobs and settings for nitric oxide concentration during evacuation.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  3. Mechanical Ventilation Duration

    The duration of mechanical ventilation.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  4. Adverse Events Incidence

    The incidence of adverse events associated with nitric oxide treatment.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  5. Complication Rate

    The complication rate, specifically focusing on Grade 3-4 intraventricular hemorrhage, intraventricular plasmalacia, moderate to severe bronchopulmonary dysplasia, retinopathy of prematurity necessitating intervention, patent ductus arteriosus requiring either medical or surgical management, pulmonary hemorrhage, and air leak syndrome.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  6. ECMO Utilization Rate

    The proportion of cases that required extracorporeal membrane oxygenation (ECMO).

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  7. Mortality Rate Before Discharge

    The mortality rate prior to discharge.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

  8. Healthcare Utilization Preferences

    Scores obtained from questionnaires assessing preferences for healthcare utilization.The Likert Scale is used in the questionnaires to measure respondents' attitudes, preferences, or perceptions. It typically ranges from 1 to 5 points, where 1 represents "Strongly Disagree" and 5 represents "Strongly Agree". Respondents select the level that best reflects their opinion, allowing researchers to quantify subjective data and analyze trends effectively.

    Time frame: Completion of evacuation (expected day 2 of evacuation)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06832163
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Oct 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 13, 2026

Study contacts

Zhicheng Zhu
Contact
jonney116@sina.com
+86 13601911685
Weiling Kong
Contact
kongwling@163.com
+8613547827448
Lin Yuan
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion